Refining basal insulin therapy: what have we learned in the age of analogues?
- 31 July 2007
- journal article
- review article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 23 (6), 441-454
- https://doi.org/10.1002/dmrr.762
Abstract
Background The basal insulin analogues glargine and detemir have been subject to a series of trials comparing their clinical profiles to the conventional preparation, neutral protamine Hagedorn (NPH). Careful review of these trials provides opportunities to learn clinically useful lessons about these insulins. Methods MedLine‐indexed trials comparing glargine or detemir to NPH were scrutinized for control, tolerability and dose data. Separate considerations were made for types 1 and 2 diabetes, and for basal–bolus and basal plus oral glucose‐lowering drugs (OGLD) therapy. Attention was paid to dosing schedules and 24‐h glycaemic profiles. Results Collectively, the trials demonstrated an improved balance between glycaemic control and tolerability for both analogues compared to NPH, regardless of regimen and diabetes type. Neither once‐daily glargine nor detemir reliably provides 24‐h basal insulin replacement in all patients with type 1 diabetes; a waning of effect frequently obliges twice‐daily administration. When added to OGLDs in type 2 diabetes, goal‐titrated once‐daily basal insulin generally lowered HbA1c by ∼1.5%, whereas twice‐daily administration tended to increase insulin dose disproportionately to improvement in control. Hence, adding bolus insulin may be a preferable intensification method to dividing the basal dose. Varying injection time or dividing the basal insulin dose predictably affects the pattern of hypoglycaemia and bolus dose requirements. Morning administration tends to require higher dosing than evening administration. Conclusions Scrutiny of trials involving glargine and detemir has increased our understanding of how best to dose basal insulins. An individualized approach is still necessary however, and several questions remain that require further research. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 57 references indexed in Scilit:
- Does insulin detemir have a role in reducing risk of insulin‐associated weight gain?Diabetes, Obesity and Metabolism, 2006
- Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetesDiabetic Medicine, 2006
- Once-daily Insulin Glargine Administration in the Morning Compared to Bedtime in Combination with Morning Glimepiride in Patients with Type 2 Diabetes: An Assessment of Treatment FlexibilityHormone and Metabolic Research, 2006
- Impact of Active Versus Usual Algorithmic Titration of Basal Insulin and Point-of-Care Versus Laboratory Measurement of HbA1c on Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 2006
- Optimal timing of injection of once‐daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal‐timesDiabetic Medicine, 2005
- Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapyInternal Medicine Journal, 2005
- Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulinDiabetic Medicine, 2005
- A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 DiabetesHormone and Metabolic Research, 2003
- New insulins in the treatment of diabetes mellitusBest Practice & Research Clinical Gastroenterology, 2002
- Comparative Trial Between Insulin Glargine and NPH Insulin in Children and Adolescents with Type I Diabetes MellitusJournal of Pediatric Endocrinology and Metabolism, 2002